MA42130A - Combinaisons d'opioïdes et de n-acyléthanolamines - Google Patents

Combinaisons d'opioïdes et de n-acyléthanolamines

Info

Publication number
MA42130A
MA42130A MA042130A MA42130A MA42130A MA 42130 A MA42130 A MA 42130A MA 042130 A MA042130 A MA 042130A MA 42130 A MA42130 A MA 42130A MA 42130 A MA42130 A MA 42130A
Authority
MA
Morocco
Prior art keywords
acylethanolamines
opioids
combinations
Prior art date
Application number
MA042130A
Other languages
English (en)
Inventor
Ephraim Brener
Elran Haber
Ascher Shmulewitz
Original Assignee
Therapix Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapix Biosciences Ltd filed Critical Therapix Biosciences Ltd
Publication of MA42130A publication Critical patent/MA42130A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/164Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
MA042130A 2015-05-21 2016-05-17 Combinaisons d'opioïdes et de n-acyléthanolamines MA42130A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562164618P 2015-05-21 2015-05-21

Publications (1)

Publication Number Publication Date
MA42130A true MA42130A (fr) 2018-03-28

Family

ID=57319619

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042130A MA42130A (fr) 2015-05-21 2016-05-17 Combinaisons d'opioïdes et de n-acyléthanolamines

Country Status (12)

Country Link
US (2) US20180116982A1 (fr)
EP (1) EP3297622B1 (fr)
JP (2) JP7244992B2 (fr)
CN (2) CN107613966A (fr)
AU (3) AU2016263292B2 (fr)
CA (1) CA2985305C (fr)
DK (1) DK3297622T3 (fr)
ES (1) ES2968345T3 (fr)
IL (2) IL305528A (fr)
MA (1) MA42130A (fr)
PL (1) PL3297622T3 (fr)
WO (1) WO2016185468A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
SG10201807034XA (en) 2017-09-05 2019-04-29 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133574A1 (fr) * 2008-04-28 2009-11-05 Vermont Italia Srl Formulation pharmaceutique contenant de l’éthanolamide palmitoyle et de l’éthanolamide stéaroyle
MX355142B (es) 2012-03-05 2018-04-05 Dr Reddys Laboratories Ltd Acetamidas heterociclicas sustituidas como agonistas del receptor opioide kappa (kor).
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
EP2944309B1 (fr) * 2014-05-14 2019-03-20 EPITECH GROUP S.p.A. Utilisation de palmitoyléthanolamide en combinaison avec des opioïdes

Also Published As

Publication number Publication date
AU2016263292A1 (en) 2017-11-30
CA2985305A1 (fr) 2016-11-24
EP3297622A4 (fr) 2019-01-02
IL305528A (en) 2023-10-01
IL255749A (en) 2018-01-31
WO2016185468A1 (fr) 2016-11-24
EP3297622B1 (fr) 2023-11-01
EP3297622A1 (fr) 2018-03-28
CA2985305C (fr) 2024-04-09
JP2018515547A (ja) 2018-06-14
JP2021138703A (ja) 2021-09-16
AU2023251499A1 (en) 2023-11-09
AU2021204517B2 (en) 2023-07-27
DK3297622T3 (da) 2024-01-22
ES2968345T3 (es) 2024-05-09
AU2021204517A1 (en) 2021-07-29
JP7244992B2 (ja) 2023-03-23
CN116808038A (zh) 2023-09-29
CN107613966A (zh) 2018-01-19
US20180116982A1 (en) 2018-05-03
US20210177779A1 (en) 2021-06-17
AU2016263292B2 (en) 2021-04-01
PL3297622T3 (pl) 2024-03-18

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
HK1249445A1 (zh) 抗分揀蛋白抗體和其使用方法
HK1252698A1 (zh) 抗siglec-9抗體及其使用方法
IL259495A (en) Antibodies and methods for using them
HK1252696A1 (zh) 抗siglec-7抗體及其使用方法
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
MA49715A (fr) Oligomères et conjugués d'oligomères
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
MA41997A (fr) Combinaisons de cannabinoïdes et de n-acyléthanolamines
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
BR112016020889A2 (pt) variantes de hppd e métodos de uso
IL282482A (en) Variants of protoxin-II and methods of use
IL282508A (en) Variants of protoxin-II and methods of use
MA42130A (fr) Combinaisons d'opioïdes et de n-acyléthanolamines
BR112018000205A2 (pt) oxiesteróis e métodos de uso destes
TH1501005200A (th) องค์ประกอบต้านจุลชีพ และ วิธีการใช้ที่เกี่ยวข้อง